Teva Pharmaceutical Industries Ltd. launched a generic version of Allergan’s Delzicol, a delayed-release capsule taken for mildly to moderately active ulcerative colitis.
- Teva said Delzicol has annual U.S. sales of about $130 million, according to IMS data as of February
- NOTE: Dec. 12, the U.S. Court of Appeals for the Federal Circuit affirmed that Mylan and Teva’s proposed generics of Delzicol didn’t infringe Allergan’s patent
Link to Statement: Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United States
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.